SVIL-AS1 and cancer: Recent translation studies have shown that lncRNAs can be knocked down by RNAi, antisense oligonucleotides (ASOs), CRISPR‐based approaches, and small molecules that target RNA‐protein interactions.[35] In the future, technological advancements may enable SVIL‐AS1 targeting in combination with PI3K‐AKT1 inhibitors for cancer therapeutics.